The cardiology news you need, beat by beat. Subscribe: https://xitter.cf/t.co/bRmGHfN7En
Joined March 2022
- Tweets1.2K
- Following158
- Followers923
- Likes976
“Just because you can doesn’t mean you should” is a good mantra to have, but a @lowninstitute study revealed it may not always be followed in cardiology. Regions with the most PCI-performing physicians lead to a disproportionately higher share of patients receiving stents they’re unlikely to benefit from.
In CW #391, we’ll dive into some reasons why, plus…
📊 A @JAMACardio study found a “U-shaped” association between left ventricular end-diastolic diameter and mortality.
💰 Braveheart Bio nabbed a $440M IPO to fund two Phase 3 trials of its cardiac myosin inhibitor.
🫀 ACCESS partnered with @JNJNews to help bring the newest cardiac technology to ASCs.
cardiacwire.com/newsletter/l…
Cardiovascular inflammation has been the talk of the town in cardiology, and while Novo Nordisk was wise to pursue treating it, results from the ZEUS trial have led to a thunderous debate on whether or not it ever played a role in ASCVD.
The ZEUS trial’s results may have struck down attempts to treat cardiac inflammation, but that might just be a good thing.
More on the implications of those flat results in CW #389. We’ll also cover…
💊 A new sub-analysis of the ATTRibute-CM trial bolsters the quality-of-life case for @BridgeBioPharma's Attruby (acoramidis).
💰 Austria’s P&F Products & Features acquired AVVie.
🏆 @nyulangone came first in @usnews’s 2026 rankings of the best hospitals for cardiac care.
cardiacwire.com/newsletter/z…
New secondary analysis data backs up Attruby’s ability to improve quality of life and symptom management for patients with ATTR-CM. In the growing market of ATTR-CM meds, @BridgeBioPharma's medication seems on course to stay competitive.
The field of cardiology relies upon data…for almost everything. Yet, academia is falling behind – why, and what does that mean for the future of the specialty?
Read more about that in CW #388. We’ll also give updates on:
🚨 Could a wristband detect cardiac arrest? A small study in The Lancet showed the answer might be yes for @Corsano_Health's CardioWatch.
✒️ @Cleerlyhealth and @Allelica_PRS inked a partnership to launch the Cleerly Polygenic Cardiovascular Risk Score Test.
✅ The FDA granted Fast Track designation to @HAYA_lncRNA's RNA-targeting drug, HTX-001.
cardiacwire.com/newsletter/f…
A common question in structural heart cardiology is “when do we know to intervene?” and recently released 25-year mitral regurgitation data might just have given us an answer.
cardiacwire.com/newsletter/m…
When is it time to intervene? Great question, and it’s one that is continuously at the forefront of cardiology. New 25-year data on mitral regurgitation published in @JAMACardio may give clinicians some clues.
Read more about that in CW #387, plus…
🤔 Why does waiting for symptoms increase AS spending?
💰 CoreMap closed a $37M Series C financing round led by medtech giant @Medtronic .
✅ @CorVistaHealth received a third FDA clearance for their cardiopulmonary CorVista System.
cardiacwire.com/newsletter/m…
A new national survey broke down the career perceptions and workload of HF cardiologists, more on that in our most recent newsletter.
Becoming a heart failure cardiologist requires at least 11 years of study, a whole lot of love, and…apparently a willingness to accept lower pay? That last one may not sound right to you, and it definitely doesn’t to HF cardiologists either. More on that in CW #386, plus…
🫀A new @JClinAnesth study showed less might really be more when it comes to anesthesia for TAVR.
📔The @ACCinTouch's updated ECDP helps clinicians sort through the evolving landscape of HFpEF.
cardiacwire.com/newsletter/h…
CW #385 is out now with news on price transparency data for cardiology – and costs may be concerningly arbitrary.
More on that, plus…
💰 Karoo Health closed a $16.2M Series A round to build what it calls an operating system for cardiovascular care.
🫀 How might RPM with @AbbottNews CardioMEMS implantable pulmonary artery pressure sensors improve HF care?
🩺 About three in five cardiovascular imaging physicians report feeling burned out.
cardiacwire.com/newsletter/w…
While the World Cup has wound down, cardiology news has only picked up.
In Issue #384 of CW, we take a look into the first ever FDA approval for an oral PCSK9i, which went to @Merck Lipfendra last week.
Plus…
🩸 Can Kerendia handle the (blood) pressure? A new @JAMACardio paper says yes.
🤖 @CorewellHealth performed the world’s first single-port robotic mitral valve repair.
💰 @joinBunkerhill banked a $25M Series B to help grow the company’s Carebricks agentic AI platform.
cardiacwire.com/newsletter/m…
Could MRI become the new norm for prostate cancer staging? A new paper from @JAMANetworkOpen compares the method to digital rectal exams across staging and metastasis-free survival, and MRI may come out on top.
An analysis by Dr. Khurram Nasir at SCCT 2026 broke down the cost of cardiac diagnostics.
cardiacwire.com/zero-cac-and…
New data from SCCT 2026 casts doubt on the CAC score’s ability to account for cardiac risk. How should clinicians care for zero CAC patients?
More on that in CW #383, plus…
💰 @Neko nabbed a hefty $700M Series C to expand their preventative screening across the U.S.
💊 Most patients with cardiovascular-kidney-metabolic syndrome aren’t getting the treatment they need
✅ @SiemensHealth home grown, CT-based coronary plaque analysis software has been cleared by the FDA
cardiacwire.com/zero-cac-and…
With so many contenders for ATTR-CM medications, what does AstraZeneca and Ionis’ unexpected Phase 3 trial failure mean for the market?
Yesterday’s top story dives into some possibilities.
CW #382 is hot off the press this morning with updates on Astrazeneca/Ionis’ Waiuna surprise Phase III failure for their ATTR-CM drug.
More on that, plus…
🤝 Bayer's new breakthrough clinical trial alliance aims to improve efficiency and investigational therapy
📈 Cardiologist pay keeps finding new peaks, rising 4.3% overall this past year
💰 U.S. healthcare continues to surge, growing 7.3% last year to a total of $5.7T
cardiacwire.com/newsletter/s…
Could a new polypill combining a beta-blocker, an SGLT2 inhibitor, and an MRA in one be the solution to getting patients to take heart failure meds? A new Nature study suggests it just may be.
CW #381 hit inboxes this morning with updates on the POLY-HF trial’s new polypill approach for treating HF. The early data seem promising, with those on the polypill showing a 60% lower rate of heart failure hospitalizations or ED visits.
More on that, plus…
- 100 hospitals received the ACC’s highest distinction – who are they?
- More big news for @JNJNews as their dual energy catheter received FDA approval.
cardiacwire.com/newsletter/h…
Clinicians get notifications all day everyday, but instead of trying to reduce them, a new study says it may be better to give them more power. Assertive notifications that have the ability to push referrals forward could be the key to improving AS management, especially for historically undertreated groups.
Read the full top story at the link below.
cardiacwire.com/detect-as-ii…
